Markets:

Overview

News

Currencies

International

Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.370 -0.060 (-2.47%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >

Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron ↗

August 02, 2022

Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN)

Via Benzinga

Dear AMC Stock Fans, Mark Your Calendars for Aug. 4 ↗

July 07, 2022

AMC Entertainment (AMC) stock is in the news today as investors in the theater company prepare for a potential catalyst coming next month!

Via InvestorPlace

Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update ↗

July 07, 2022

Annovis Bio (ANVS) stock is soaring higher on Thursday following a positive update from the FDA for its buntanetap clinical trial.

Via InvestorPlace

FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap ↗

July 07, 2022

Via Benzinga

Annovis Bio Gets FDA Nod For Late-Stage Parkinson Disease Study Amendments ↗

July 07, 2022

The United States Food and Drug Administration (FDA) announced clearance for amendments to Annovis Bio’s (NYSE: ANVS) Phase 3 clinical study of Buntanetap for the treatment of Parkinson's disease.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 07, 2022

Via Benzinga

83 Biggest Movers From Yesterday ↗

June 09, 2022

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...

Via Benzinga

50 Stocks Moving In Wednesday's Mid-Day Session ↗

June 08, 2022

Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022 ↗

May 02, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease ↗

January 25, 2022

Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 27, 2021

Gainers OptiNose (NASDAQ:OPTN) shares mov...

Via Benzinga

Annovis Bio on Its Positive Results in Alzheimer's and Parkinson's Clinical Trials ↗

December 27, 2021

Image provided by Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 03, 2021

Gainers Lixte Biotech Holdings (NASDAQ:LIXT

Via Benzinga

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market ↗

October 21, 2021

Cortexyme is testing a twice-day pill to treat Alzheimer's disease.

Via Investor's Business Daily

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

44 Biggest Movers From Yesterday ↗

October 15, 2021

Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

3 Stocks Insiders Are Buying ↗

October 14, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo ↗

October 05, 2021

Annovis Bio Inc (NYSE: ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD). Data from 54 patients found that once-...

Via Benzinga

The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO ↗

August 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...

Via Benzinga

Better Biotech Stock: Cassava Sciences vs. Annovis Bio ↗

August 26, 2021

It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment.

Via The Motley Fool

Why Is Biogen Pursuing a New Direction in Alzheimer's Research? ↗

August 13, 2021

It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.

Via The Motley Fool

61 Biggest Movers From Yesterday ↗

August 03, 2021

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program....

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

40 Stocks Moving In Monday's Mid-Day Session ↗

August 02, 2021

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:...

Via Benzinga

63 Biggest Movers From Friday ↗

August 02, 2021

Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Annovis Bio, Inc. Common Stock (NY:ANVS)

Headline News about Annovis Bio, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today